Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure

Roya  Atabakhshian; Faranak Kazerouni; Fariba  Raygan; Hushang  Amirrasouli; Ali  Rahimipour; Nezhat  Shakeri

International Cardiovascular Research Journal

The Official Annually Journal of Cardiovascular Research Center, Shiraz University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards & Committees Indexing and Listing Sources Journal Metrics Publication Ethics and Publication Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure

Author(s):

Roya Atabakhshian¹,

Faranak Kazerouni^1,*,

Fariba Raygan²,

Hushang Amirrasouli¹,

Ali Rahimipour¹,

Nezhat Shakeri³

1Department of Laboratory Medicine, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2Heart Department, Shahid Beheshti Hospital, Shahid Beheshti University of Medical Sciences, Kashan, Iran

3Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

International Cardiovascular Research Journal:Vol. 8, issue 4; e11675

Published online:Dec 01, 2014

Article type:Research Article

Received:Apr 19, 2017

Accepted:May 14, 2014

How to Cite:Roya AtabakhshianFaranak KazerouniFariba RayganHushang AmirrasouliAli RahimipourNezhat Shakeriet al.Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure.Int Cardiovasc Res J.8(4):e11675.

Abstract

Background: Galectin-3 is a soluble ß-galactoside–binding lectin released by activated cardiac macrophages. Galectin-3 has been proposed for diagnosis and prognosis of HF patients.

Objectives: The present study aimed to investigate the relationship between galectin-3 as a biomarker and ejection fraction and functional capacity in the patients with compensated systolic heart failure.

Patients and Methods: In this study, serum levels of Galectin-3 were measured in 76 patients with compensated heart failure with New York Heart Association class I–IV and left ventricular ejection fraction < 45%. Galectin-3 was measured by an ELISA kit. Besides, echocardiography was used to evaluate left ventricular ejection fraction. Additionally, functional capacity was determined based on the patients’ ability to perform a set of activities. After all, the data were analyzed used t-test, Kruskal-Wallis, one–way ANOVA, and chi-square test. P < 0.05 was considered as statistically significant.

Results: The patients’ age ranged from 45 to 75 years, with the mean age of 63.85 ± 9 years. In addition 57.9% of the patients were male. The results revealed no significant correlation between Galectin-3 and age, body mass index, and estimated glomerular filtration rate. Also, no significant correlation was observed between Galectin-3 levels and left ventricular ejection fraction (P = 0.166) and functional capacity (P = 0.420). Yet, a significant difference was found between males and females regarding the mean of Galectin-3 (P = 0.039).

Conclusions:: The study results suggested that Galectin-3 could not be used as a marker of disease progression in the patients under treatment, which could probably be the result of medication use in these patients.

Keywords

Galectin-3

Heart Failure

Functional Capacity

Fulltext

The full text is available in PDF.

References

1.
The references are available in PDF.

comments